News

FELIQS became the only Bio2023 Start-up Stadium finalist from Japan

https://www.bio.org/events/bio-international-convention/start-stadium-2023

May 15, 2023

FELIQS became RESI Boston June Innovator’s Pitch Challenge (IPC) finalist

https://resiconference.com/pitch-challenge/

April 28, 2023

Completed 2.5M seed funding by allocation of new shares to a third party

September 22, 2022

Mission

To create the society without people left behind

In an aging society with a declining birthrate, it is important not only to extend healthy life expectancy, but also to maintain the number of healthy children. We try to solve the problems of both pediatric and aging diseases.

About FELIQS

Developing novel medicines
targeting ferroptosis / oxidized lipid

FELIQS【fíːlɪks】 is a preclinical-stage start-up company established based on the robust science from molecular pathobiology, department of pharmaceutical science, Kyushu university.

Ferroptosis is a new type of cell death reported in 2012(Cell. 2012 May 25;149(5):1060-72.), and it is caused by the accumulation of oxidized lipids. In recent years, it has been reported to be associated with many diseases such as cancer, ischemia-reperfusion injury, and neurodegenerative diseases, and is being investigated as a new drug target. We have established a unique drug discovery platform targeting ferrotosis/oxidized lipids, and are now conducting preclinical research toward the clinical trial to create new medicine for unmet medical needs in ophthalmology space.

Name: FELIQS CORPORATION
Address: 1-1 Hyakunenkoen, Kurume, Fukuoka, 8390864, JAPAN
Capital: 50,500,000 JPY
Main bank: MUFG bank
Investors: Mitsubishi UFJ Capital, Keio Innovation Initiative, FFG Venture Business Partners, Kurume Research Park

Business

Pipeline

Code	Target Indications	administration Route	Regulatory Pathway	Preclinical			Clinical
Code	Target Indications	administration Route	Regulatory Pathway	Discovery / Research	Lead optimization	IND enabling	Phase I/II
FLQ-101	Retinopathy of Prematurity (ROP)	Intravenous	505(b)(2)
FLQ-104	Geographic Atrophy / wet AMD	Oral	505(b)(1)

Member

Ken-ichiro Kuninobu,
Ph.D., RPh

Co-founder and CEO

Dr.Kuninobu has 15 years+ experience in the pharmaceutical industry. He led the US regulatory and clinical affairs of the department of regenerative medicines in NIPRO until 2022 in collaboration with Yale University

Ken-ichi Yamada,
Ph.D.

Co-founder and CSO

Professor of Kyushu University. Dr.Yamada is the Principal investigator of basic research on elucidation of disease mechanisms and drug discovery by targeting oxidized lipids. He worked as a research fellow in NIH(NIH/NCI: Dr. Murali C. Krishna)

Samir Tari,
M.D., MBA

Consultant Medical Director

Dr.Tari has 16 years+ experience as a pharmaceutical executive in ophthalmology. He served as Senior Director of Medical Affairs at Regeneron, Global Medical Lead, and Senior Medical Director at Astellas.

Aiko Kato Sullenberger

Boston Operations Manager

Aiko has ten years of experience in research and business development in Daikin Global HQ. She handles its CVC operation in Boston up to 2020. In Allm USA, she engaged in scouting opportunities to digital health solutions to US medical institutions. Experience at CIC expanded her network of life science and VCs in greater Boston area.

Advisors

Robert M. Ward, M.D.

Professor Emeritus

Dr.Ward was the former chair of the American Academy of Pediatrics Committee on Drugs began the Pediatric Pharmacology Program at the University of Utah School of Medicine and served as an attending neonatologist and medical director of the Primary Children’s Hospital NICU. He has published widely and lectured internationally.

Darius M. Moshfeghi, M.D.

Chief of Retina Professor of Ophthalmology Stanford University School of Medicine

Dr.Moshfeghi is an internationally-recognized expert in pediatric vitreoretinal disease and pediatric retinal telemedicine. He has dedicated his career to using telemedicine and digital technology to prevent blindness in children.

Kenichi Shimada, Ph.D.

Research Associate
Laboratory of Systems Pharmacology Harvard Medical School

Dr.Shimada received his Ph.D. for the elucidation of the mechanisms of ferroptosis, a form of non-apoptotic cell death phenotype, under the supervision of Dr. Brent Stockwell at Columbia Univeristy. In 2015, he came to HMS and continued his training as a postdoctoral fellow with Dr. Timothy Mitchison and has published a few papers in mechanistic toxicology and cancer signaling.

Dr. Norman Barton, M.D., Ph.D

Ex-Global Head Clinical Sciences Rare Metabolic Disorders and Neonatology in Takeda(Shire)

Dr.Barton is an experienced executive with substantive accomplishments in rare diseases. He has 40 years of experience in orphan drug product development in leadership positions with strategic, operational, and management responsibilities at Takeda and Shire, including the retinopathy of prematurity (ROP) program.

Robert Bhisitkul, MD, Ph.D

Professor of Retina of UCSF.

Dr.Bhisitkul is an ophthalmologist and retina specialist who provides medical and laser treatment for macular degeneration, diabetic retinopathy and other retinal diseases. He also performs surgery on macular hole and macular pucker, retinal detachment and complications of diabetic eye disease.

Contact

Feel free to write down your inquiry in the following form.

Please enter here to input your inquiries

Every Life Deserves A Bright Future